PR Newswire press releases
Full-text press releases distributed by PR Newswire, newest first. Times are US Eastern.
Source: PR Newswire
Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
Today, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek® 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy® injection or Wegovy® pill.1,2 Both retrospective cohort analyses used de-identified patient data from the Ro telehealth platform and a validated seven-item questionnaire to assess food noise, defined as persistent, intrusive and unwanted thoughts about food.3
Beyond Psilocybin: Sangam Healing Center Introduces a Unique Integrated approach to Natural Medicine and Personal transformation in Colorado
Sangam Healing Center is introducing a distinctive, integrative approach to natural medicine and personal transformation in Colorado, bringing together traditional healing practices, contemporary psychological perspectives, and time-honored wisdom traditions.
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Washington, D.C. The presentations span clinical trial results, patient-reported outcomes and real-world evidence and reflect Lilly's commitment to advancing potential treatment options that address health outcomes, day-to-day experiences and the diverse needs of people living with complex chronic diseases.
Study of 11,365 Adults: Nearly 10% Weight Loss, Kept Off for Two Years Without Medication
Adults in Key to Health's metabolic health program lost an average of 9.6% of their body weight over two years without medication, according to a study of 11,365 people published today in Obesity, the journal of The Obesity Society.
Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg.1 The results were presented at ObesityWeek® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology.1,2
EFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026
EFICYENT, a cross-border payment platform, is going to attend the Singapore FinTech Festival (SFF) 2026, which is going to be one of the world's largest gatherings of the global financial and technology ecosystem. It will take place between November 18 - 20, 2026, at Singapore. This event will converge policymakers, financial institutions, fintech companies, and investors to discuss the developments that are going to shape the future of fintech.
Breakthrough T1D Honors World Diabetes Day with Expanded Global "See T1D" Campaign, Spotlighting Life with Type 1 Diabetes
In honor of World Diabetes Day, November 14, Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced the continuation and global expansion of its impactful "See T1D" campaign. The out-of-home marketing campaign can be seen throughout November, National Diabetes Awareness Month. A marquee element of the campaign is today's Times Square digital billboard takeover, with ads featuring two Breakthrough T1D celebrity advocates who live with T1D, Peloton head instructor and Project Swagger host, Robin Arzón and 2025 U.S. Open & 3x PGA Tour champion, J.J. Spaun. T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. It requires constant, lifelong management, and can be diagnosed at any age regardless of diet or family history.
Webull Corporation (BULL) Investors: December 7, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Webull Corporation ("Webull") (NASDAQ: BULL) on behalf of those who purchased or acquired Webull securities between April 26, 2025 and October 6, 2026, inclusive. The lawsuit is filed in the United States District Court for the Middle District of Florida and is captioned Ward v. Webull Corporation, No. 8:26-cv-03052 (M.D. Fla.). Investors have until December 7, 2026, to file for lead plaintiff status.
Chinese modernization: New achievements, new opportunities for Asia-Pacific and the world
A report from People's Daily:
SmallRig Joins Art World Figures to Discuss Creativity and Authenticity in the AI Era--and How Art and Technology Can Drive Innovation
As generative AI changes how images are made, one question grows more urgent: what still belongs to the human behind the lens? On November 11, Shenzhen International Art Museum and SmallRig, the imaging-gear brand built for creators, took up that question together by hosting an international exchange on how art and technology ecosystems are being reshaped in the AI era.
EFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026
EFICYENT, a cross-border payment platform, is going to attend the Singapore FinTech Festival (SFF) 2026, which is going to be one of the world's largest gatherings of the global financial and technology ecosystem. It will take place between November 18 - 20, 2026, at Singapore. This event will converge policymakers, financial institutions, fintech companies, and investors to discuss the developments that are going to shape the future of fintech.
Fluence Energy (FLNC) Shares Tumble Again - This Time on Top Executives' Departures; Securities Class Action Pending
On November 2, 2026, investors in Fluence Energy (NASDAQ: FLNC) saw the price of their shares continue to tumble – this time, the shares fell almost 9% after the company announced CEO Julian Nebreda and CFO Ahmad Pasha departed on October 30, 2026.
Better Home & Finance Holding Company (BETR) Down 61% Between May 6 and August 6, 2026; Class Period Expanded to End August 6, 2026
The Class Period in the investor lawsuit against Better Home & Finance Holding Company (NASDAQ: BETR) has been expanded. The recently filed related securities class action seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between March 13, 2026 and August 6, 2026. The November 20, 2026 Lead Plaintiff deadline remains the same.
APP INVESTOR ALERT: AppLovin Investors with Substantial Losses Have Opportunity to Lead the AppLovin Class Action Lawsuit
Hagens Berman, a leading securities litigation law firm, is actively investigating alleged federal securities law violations by AppLovin Corporation (NASDAQ: APP) in a pending securities class action. The suit alleges AppLovin executive leadership issued materially false or misleading statements regarding the readiness, integration, and adoption of its artificial intelligence (AI) models and self-service ad tools.
PASCAL Unveils Its 2026 Holiday Gift Edit, Featuring Timeless Watches and Color-Driven Gifts
PASCAL, the Los Angeles-born jewelry and watch brand known for its color-led approach to modern design, today announced its 2026 Holiday Gift Edit, launching November 14. Led by the Timeless Classic Collection, the edit brings together refined watches, coordinated gifts and seasonal offerings designed to make holiday gifting feel more personal.
AJOVY® Formally Included in China's National Reimbursement Drug List 2026
On November 14, NeuroGen announced that it's in-licensed innovative drug AJOVY® (fremanezumab injection) from TEVA has been successfully listed on China's National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first CGRP inhibitor covered by national insurance, AJOVY® achieved same-year NRDL inclusion after its initial approval in June—a milestone expected to dramatically improve patient access and relieve the long-term financial burden for patients in China living with migraine.
61% of Older Workers Already Tapping Retirement Savings to Cover Expenses
LiveCareer®, a trusted online resume builder, reveals that retirement may be further out of reach than ever for older Americans. Based on responses from 878 U.S. workers aged 50 and over, the Retirement Reality Check report paints a stark picture: retirement is no longer a milestone, it's a moving target, shaped by inflation, health costs, and financial instability. Due to market volatility in recent months, a full 75% of respondents say they have delayed retirement due to stock market volatility, and 91% report that inflation or tariffs have impacted their retirement plans.
Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Suit Against El Pollo Loco, Inc., for Alleged Failure to Reimburse Employees' Business Expenses
The Los Angeles employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action complaint alleging that El Pollo Loco, Inc. violated the California Labor Code. The El Pollo Loco, Inc. class action lawsuit, Case No. CVRI2606104, is currently pending in the Riverside County Superior Court of the State of California. A copy of the Complaint can be read here.
Luvme Hair Highlights Long Wig Hairstyles for Winter 2026
Luvme Hair is showcasing a selection of long wig hairstyles for Winter 2026, featuring different textures, colors, and constructions for customers seeking seasonal style inspiration.
Advanta To Strengthen Market Presence in Africa with Strategic Acquisition of Hytech
Advanta had entered into an agreement on August 15, 2026 to acquire Hytech Egypt USA LLC, the holding company of Misr Hytech Seed International S.A.E. ("Misr Hytech" or the "Company"), from Helios Investment Partners ("Helios") and The Egyptian-American Enterprise Fund ("EAEF") which is advised by Lorax Capital Partners. The transaction has received antitrust approvals from the COMESA Competition and Consumer Commission and the Egyptian Competition Authority and is expected to close on or before January 31, 2027, subject to the satisfaction of the customary closing conditions.
L.A.B. Golf Introduces MEZZ.2i, Refining an Icon That Helped Drive Zero Torque Revolution
L.A.B. Golf, renowned for pioneering Lie Angle Balance (L.A.B.) technology in putting, today introduced MEZZ.2i, the first refresh of its MEZZ putter in more than four years. Building on the legacy of MEZZ.1, MEZZ.2i improves on the original with a more refined shape, enhanced feel, and two ways to pick up the ball.
Beko Calls for Climate, Trade, and Finance Policies to Align as Carbon Rules Reshape Manufacturing
Beko used its COP31 panels to make the case that climate, trade and industrial policies need to work together, and that finance has to follow, if climate action is to strengthen industrial competitiveness rather than erode it. Fatih Özkadı, Chief Sustainability, Quality, and Customer Care Officer, and Barış Alparslan, Chief Financial Officer, took that message to their panels during the summit's first week.
CARsgen's CAR-T Product Satri-cel Included in China's Commercial Health Insurance Innovative Drug List
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that satricabtagene autoleucel ("satri-cel", product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the Commercial Health Insurance Innovative Drug List (2026) (the "CHIIDL") issued by the National Healthcare Security Administration ("NHSA") and the Ministry of Human Resources and Social Security ("MOHRSS"), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. The new list was published today by the NHSA at a press conference held in Suzhou, and will officially take effect on January 1, 2027.
Chinese Team Drops a "Game-Changer": Motphys Launches MotrixSim 1.0, Sparking Industry Buzz
If the global expansion of Chinese-made robots defined the hardware boom in the first half of the embodied AI race, the second half will be won by those that can bring down the high cost of real-world trial and error and make robot training more universal and accessible. In this underlying physics engine race long dominated by Western players, a Chinese team is now bringing a potential game-changer to the field.
Beko Calls for Climate, Trade, and Finance Policies to Align as Carbon Rules Reshape Manufacturing
Beko used its COP31 panels to make the case that climate, trade and industrial policies need to work together, and that finance has to follow, if climate action is to strengthen industrial competitiveness rather than erode it. Fatih Özkadı, Chief Sustainability, Quality, and Customer Care Officer, and Barış Alparslan, Chief Financial Officer, took that message to their panels during the summit's first week.
MV Transportation Supports the Nomination of Mark Aesch to serve as FTA Administrator
MV Transportation strongly supports the nomination of Mark Aesch to serve as Administrator of the Federal Transit Administration and urges the Senate to act swiftly to confirm him.
uSMART Securities Singapore Marks Third Branch Opening in Bugis with Lion Dance and K-pop
uSMART Securities Singapore officially opened its third branch at 516 North Bridge Road, #01-00, Singapore 188740 expanding its physical presence in Singapore with a new uSMART Investor Hub. The opening was marked by a private ceremony featuring a speech, a traditional lion dance and a K-pop dance performance, bringing together the uSMART team, esteemed guests and partners.
HiTHIUM Partners with the University of Cambridge to Advance International Industry-Academia Collaboration in Long-Duration Energy Storage
On November 12, the Global Energy Storage Colloquium was held in Xiamen. During the colloquium, HiTHIUM and the University of Cambridge signed a memorandum of understanding (MoU), establishing a strategic partnership. The two parties will collaborate on frontier scientific research, key technology innovation and industrial applications in battery energy storage, bringing academic research into closer alignment with industry needs and exploring new models for international industry-academia collaboration. The partnership aims to contribute to the advancement of global energy storage technology and the industry.
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.
The NYSE Welcomes vVARDIS as a Publicly Listed Company
vVARDIS (NYSE: VVVV) co-founders Dr. Haley Abivardi and Dr. Goly Abivardi aim to reshape the future of dental care with a drill-free treatment for the world's #1 non-communicable disease: cavities.
Innovative Immunology Biotech Windward Bio Lists on Nasdaq
Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners' 11th IPO in 2026.
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfully included in the updated National Reimbursement Drug List (2026) (the "NRDL").
Innovative Immunology Biotech Windward Bio Lists on Nasdaq
Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day,up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners' 11th IPO in 2026.
LaserAway, Nation's Largest Aesthetic Dermatology Brand, Opens Its 244th Clinic
LaserAway, the nation's leader in aesthetic dermatology today announced the opening of its 244th location in Willowbrook, IL. The opening celebrates the company's 20th Anniversary which takes place this year and reflects two decades of continuous growth without a single clinic closure, a rare achievement in retail and the medical aesthetics category.
Manhattan Associates Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Manhattan Associates, Inc. - MANH
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Manhattan Associates, Inc. ("Manhattan") (NasdaqGS: MANH).
Millrose Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Millrose Properties, Inc. - MRP
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 8, 2026 to file lead plaintiff applications in a securities class action lawsuit against Millrose Properties, Inc. ("Millrose" or the "Company") (NYSE: MRP), if they purchased or otherwise acquired Millrose Properties, Inc. securities between February 7, 2025 and October 2, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of Florida.
Honeywell Aerospace Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Honeywell Aerospace, Inc. - HONA
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against Honeywell Aerospace, Inc. ("Honeywell Aerospace" or the "Company") (NasdaqGS: HONA), if they purchased Honeywell Aerospace, Inc. shares on the open market between June 29, 2026 and September 1, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Arizona.
Gildan Activewear Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Gildan Activewear Inc. - GIL
- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 14, 2026 to file lead plaintiff applications in a securities class action lawsuit against Gildan Activewear Inc. ("Gildan" or the "Company") (NYSE: GIL), if they purchased or otherwise acquired the Company's publicly traded securities between February 19, 2025 and June 15, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of New York.
Everest Group Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Everest Group, Ltd. - EG
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Everest Group, Ltd. ("Everest" or the "Company") (NYSE: EG), if they purchased or otherwise acquired Everest common stock between February 8, 2024 and October 27, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Ensign Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Ensign Group, Inc. - ENSG
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Ensign Group, Inc. ("Ensign" or the "Company") (NasdaqGS: ENSG), if they purchased or otherwise acquired The Ensign Group, Inc. securities between February 10, 2022 and June 18, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.
Duolingo Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Duolingo, Inc. - DUOL
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against Duolingo, Inc. ("Duolingo" or the "Company") (NasdaqGS: DUOL), if they purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Pennsylvania.
Chemours Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Chemours Company - CC
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.
Greenberg Traurig's Brad Kaufman Named Best Mentor by The American Lawyer
Global law firm Greenberg Traurig, P.A. Senior Chairman and Global Chairman of Professional Development and Integration Brad Kaufman received The American Lawyer Industry Awards' Best Mentor recognition.
WeFetch AI Corp. Is the New Name of GreenCore Solutions Corp.
WeFetch AI Corp., the artificial intelligence (AI) shopping company formerly named GreenCore Solutions Corp., has completed its change of name. The Registrar of Companies for British Columbia issued the Certificate of Change of Name on November 13, 2026.
Hanoi Emerges as 2026's Fastest-Growing Solo Travel Destination, Agoda Reports
Hanoi recorded the fastest growth in accommodation searches among solo travelers in 2026, with searches rising 22% in the second half of the year, according to digital travel platform Agoda.
Agoda Matches Five Travel Archetypes with Five Asian Destinations
Digital travel platform Agoda outlines five traveler archetypes drawn from its 2027 Asia Travel Pulse, along with the Asian destination that fits each. The survey points to fewer but longer trips, a stronger pull toward food and culture, and growing interest in quieter places and time outdoors. Value also matters, with nearly three in four Asian travelers (73%) planning to spend USD 100 or less per night on accommodation.
SUPERINTENDENCY OF INDUSTRY AND COMMERCE CLOSES THE INVESTIGATION INITIATED AGAINST ECOPETROL AND ITS SUBSIDIARIES CENIT AND OCENSA
Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) ("Ecopetrol" or the "Company") hereby informs that, by Resolution No. 88976 of 2026 (the "Resolution"), the Superintendency of Industry and Commerce of Colombia (Superintendencia de Industria y Comercio, or "SIC") notified the Company and its subsidiaries Transporte y Logística de Hidrocarburos S.A.S. ("CENIT") and Oleoducto Central S.A. ("OCENSA" and, together with Ecopetrol and CENIT, the "Ecopetrol Group") of the closure of the administrative investigation initiated in 2024. The Company disclosed the initiation of that investigation through this same channel in May 2024. The investigation sought to determine whether the Ecopetrol Group had violated the legal framework governing the protection of free economic competition, specifically the prohibition under Article 1 of Law 155 of 1959, in connection with the alleged steering of the contracting processes for helicopter services conducted between 2011 and 2023.
WeFetch AI Corp. Is the New Name of GreenCore Solutions Corp.
WeFetch AI Corp., the artificial intelligence (AI) shopping company formerly named GreenCore Solutions Corp., has completed its change of name. The Registrar of Companies for British Columbia issued the Certificate of Change of Name on November 13, 2026.
Jackson's AMTC to Open State-of-the-Art ManuTech Prototyping Center
Startups and small to medium-sized manufacturers in the Jackson region will soon be able to go from idea to physical prototype in a single afternoon. The Advanced Manufacturing Training Center (AMTC) consortium, a partnership between the Lean Rocket Lab, Jackson Area Manufacturers Association (JAMA) and Shop Rat Foundation, will open its new ManuTech Prototyping Center with a ribbon cutting on Dec. 14, 2026.
Source: PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.